Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
2 mg | In stock | $ 68.00 | |
5 mg | In stock | $ 113.00 | |
10 mg | In stock | $ 178.00 | |
25 mg | In stock | $ 343.00 | |
50 mg | In stock | $ 539.00 | |
100 mg | In stock | $ 778.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 125.00 |
Description | Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension. |
In vivo | GB002 dose- and time-dependently induces lung BMPR2 protein expression.GB002-mediated inhibition of lung PDGFRα/β phosphorylation in healthy Sprague Dawley rats immediately post inhalation[1]. |
Synonyms | GB002 |
Molecular Weight | 469.54 |
Formula | C27H27N5O3 |
CAS No. | 1619931-27-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (212.98 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Seralutinib 1619931-27-9 Angiogenesis Tyrosine Kinase/Adaptors PDGFR PK 10571 GB-002 inhibit arterial PK10571 GB 002 PK-10571 PAH Pulmonary hypertension Inhibitor GB002 Platelet-derived growth factor receptor inhibitor